ARCHIVES

FDA Ceases Exclusion Of Women From Early Drug Studies

This article is from The Cancer Letter archive.

Vol. 19 No. 19 | May 7, 1993

Download PDF Visit The Full Archive

Related Articles

ODAC Reviews Post-Marketing Studies for Eight Indications

February 21, 2003

NCI Warns Of Pill’s Potential Tumor Threat

April 2, 1976

GA101 Associated with Better PFS In Phase III Trial Versus Rituximab in CLL

July 26, 2013

In Brief: NVI Delays Release Of Laetrile Study Result; DCCRC’s New Name: Div. Of Extramural Affairs

August 25, 1978

Weight Gain After Diagnosis Increases Risk Of Death

December 28, 2007

In Brief: Basic Science Center Funding Plan Clarified; Janice Feldman Leaves As Chief Of NIH Nursing

February 17, 1989